Conference Reports for NATAP

AASLD 60th Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA, Hynes Convention Center October 30-November 3, 2009 Back

Combination Therapy With A Nucleoside Polymerase (RG7128) And Protease (RG7227/ITMN-191) Inhibitor In HCV: Safety, Pharmacokinetics, And Virologic Results From INFORM-1       Reported by Jules Levin AASLD Nov 3 2009, Boston, MA   EJ Gane, SK Roberts, CA Stedman, PW Angus, B Ritchie, R Elston, D Ipe, PN Morcos, I Najera, T Chu, MM Berrey, WZ Bradford, M Laughlin, NS Shulman, PF Smith Auckland Clinical Studies, Auckland, New Zealand; The Alfred, Melbourne, Australia: Christchurch Clinical Studies, Christchurch, New Zealand; Austin Hospital, Heidelberg, Australia; Royal Adelaide Hospital, Adelaide, Australia; Roche Palo Alto LLC, Palo Alto, CA; Pharmasset, Inc., Princeton, NJ; Intermune, Inc., Brisbane, CA, USA from 2 different studies